Tresiba, a daily basal insulin injection, received its first regulatory approval in September 2012 and has since been approved in more than 80 countries globally, including the UK and US.

Novo Nordisk said it will cut the list prices in the U.S. of two of its insulin drugs, Tresiba (insulin degludec) and Fiasp (insulin aspart), by more than 70% starting Jan. 1, 2026. Fiasp's price ...

The last study in this program, QWINT-5, compares efsitora to Tresiba in type I diabetes (T1D) patients treated with multiple daily injection therapy. Year to date, Eli Lilly’s shares have ...

Novo Nordisk's long-acting insulin Tresiba is set to gain new hypoglycaemia prevention claims in Europe, giving it an advantage over Sanofi’s top-selling Lantus. Europe's CHMP committee has just ...